RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Gilead Sciences Inc.

A collection of news and information related to Gilead Sciences Inc. published by this site and its partners.

Top Gilead Sciences Inc. Articles

Displaying items 12-22
  • AbbVie profit jumps 7% on strong Humira sales

    AbbVie profit jumps 7% on strong Humira sales
    AbbVie Inc. posted better-than-expected first-quarter earnings on Friday, propelled by another strong quarter of sales of the blockbuster drug Humira. The North Chicago-based pharmaceutical company said Friday that revenue rose 5.4 percent to $4.56...
  • Obamacare enrollment nears 1.4 million in California exchange

    Obamacare enrollment nears 1.4 million in California exchange
    Covered California signed up more than 200,000 consumers for Obamacare coverage after extending its enrollment deadline by two weeks, bringing the statewide total to nearly 1.4 million people. The health insurance exchange gave people until Tuesday to...
  • U.S. lawmakers ask Gilead to justify hepatitis C drug's $84,000 price

    U.S. lawmakers ask Gilead to justify hepatitis C drug's $84,000 price
    U.S. lawmakers have asked Gilead Sciences Inc. to justify the price of its new $84,000 drug for hepatitis C patients amid growing concern about the high cost to taxpayers and consumers. In a letter to the Foster City, Calif., company Thursday, Rep....
  • Gilead Sciences' $84,000 price for hepatitis drug is scrutinized

    U.S. lawmakers have asked Gilead Sciences Inc. to justify the price of its new $84,000 drug for hepatitis C patients amid growing concern about the high cost to taxpayers and consumers. In a letter to the Foster City, Calif., company, Rep. Henry A....
  • GLCCB to host forum on pre-exposure HIV treatment for at-risk populations

    GLCCB to host forum on pre-exposure HIV treatment for at-risk populations
    Local medical professionals will gather with members of Baltimore's gay community later this month to discuss a new medical treatment that involves HIV-negative patients taking a daily pill to avoid becoming infected. The April 28 forum, hosted by the...
  • Nasdaq plunges on tech stock sell-off

     Nasdaq plunges on tech stock sell-off
    A plunge in once-soaring technology shares sent Nasdaq into a triple-digit decline and yanked the rest of the stock market down with it. Erstwhile darlings such as Netflix Inc. and Facebook Inc., as well as biotechnology highfliers such as Intercept...
  • The $84,000 hepatitis drug [Letter]

    It was interesting to read that there is now a cure for hepatitis C in the form of new drugs that are capable of completely suppressing the virus in 90 percent of patients in 8 to 12 weeks ("Gilead Sciences' $84,000 price for hepatitis drug is...
  • Prices of new hepatitis C drugs are tough to swallow for insurers

    A pair of new drugs to treat hepatitis C offer a cure for millions of Americans afflicted with the disease — but at a potentially staggering cost to taxpayers and health plans. Until now, therapies for hepatitis C helped only about half of...
  • HIV: we can and must get to zero [Commentary]

    HIV: we can and must get to zero [Commentary]
    The havoc that HIV can wreak on a family and a community can be devastating. Over the past three decades, we have watched helplessly as friends and family members died from HIV-related illnesses. Each one lived life brimming with hope and energy, prepared...
  • From intern to T. Rowe Price portfolio manager

    From intern to T. Rowe Price portfolio manager
    A decade ago, Taymour Tamaddon was an MBA. student with a background in physics trying to convince Baltimore-based money manager T. Rowe Price to hire him as an intern. Not only did Price give him the internship and hire him later as a health care...
  • FDA approves Gilead's four-drug HIV treatment

    FDA approves Gilead's four-drug HIV treatment
    (Reuters) - U.S. health regulators on Monday approved Gilead Sciences Inc's four-drug combination pill to treat HIV, the virus that causes AIDS. The four drugs in one pill, which was formerly called the Quad and had been considered one of Gilead's more...